Fresh data backs Amplia push against pancreatic, ovarian cancer
Amplia Therapeutics' lead drug narmafotinib showed promising results against pancreatic cancer in laboratory studies led by Sydney's Garvan Institute, targeting tumor fibrosis and chemotherapy resistance. The focal adhesion kinase inhibitor demonstrated reduced tumor spread and enhanced anti-tumor activity when combined with chemotherapy.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 31 Jul 2026, 03:15 UTC · Updated 31 Jul 2026, 03:30 UTC
Summary by OZbrief Editorial. Original report: SMH. Editorial policy · Corrections